Latest Breaking News On - Matt pauls - Page 1 : comparemela.com

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

Savara Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Pharma gmbMatt paulsSavara incExpanded accessQuarter financial resultsNebulizer systemPrivate securities litigation reform actConsolidated statements

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesBruce trapnellTisha wangPharma gmbMatt paulsTrillium healthInternational conferenceSavara incNovel laboratory test for the detectionAmerican thoracic societyIndustry theaterHealthcare burdenPulmonary alveolar proteinosisImproving outcomesRare lung disease

Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pharma gmbAli atayaMatt paulsAnne ericksonClinical laboratory improvement amendmentsTrillium healthUniversity of floridaSavara incDivision of pulmonaryAssociate professorCritical careNebulizer systemPrivate securities litigation reform act

Savara Reports Third Quarter Financial Results and Provides Business Update

Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial Remains On-Track to Read Out by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution , a novel.

Pharma gmbMatt paulsSavara incQuarter financial resultsNebulizer systemPrivate securities litigation reform actConsolidated statements

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024

South koreaUnited statesUnited kingdomPharma gmbMatt paulsSavara incDrug administrationHealthcare products regulatory agencyBreakthrough therapy designationNew england journalPromising innovative medicineInnovative passport designationNorth americaRespiratory questionnaireTotal scoreComponent score